PMID- 19129735
OWN - NLM
STAT- MEDLINE
DCOM- 20100920
LR  - 20211020
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 53
IP  - 1
DP  - 2009 Jan
TI  - Sera from patients with diabetes do not alter the effect of mammalian target of 
      rapamycin inhibition on smooth muscle cell proliferation.
PG  - 86-9
LID - 10.1097/FJC.0b013e318195b588 [doi]
AB  - Clinical studies of drug-eluting stents delivering the mammalian target of 
      rapamycin (mTOR) inhibitor, rapamycin (Sirolimus), have demonstrated a reduced 
      efficacy for these devices in patients with diabetes, which suggests that the 
      mTOR pathway may cease to be dominant in mediating the vascular response to 
      injury under diabetic conditions. We hypothesized that changes in serum 
      composition accompanying diabetes may reduce the role of mTOR in mediating the 
      vascular response to injury. We measured the ability of a median dose of 
      rapamycin (10 nM) to inhibit the proliferation of human coronary artery smooth 
      muscle cells (huCASMCs) stimulated with serum obtained from donors with diabetes 
      (n = 14) and without diabetes (n = 16). In an additional analysis, we compared 
      the effects of rapamycin on huCASMCs stimulated with the serum of donors with 
      metabolic syndrome (n = 15) versus those without (n = 7). There was no difference 
      in the effect of rapamycin on huCASMC proliferation after stimulation with serum 
      from either donors with diabetes or donors with metabolic syndrome compared with 
      the respective controls. We conclude that the changes in the serum composition 
      common to diabetes and metabolic syndrome are insufficient to diminish the role 
      of mTOR in the progression of cardiovascular disease.
FAU - Moss, Stephanie C
AU  - Moss SC
AD  - Ochsner Clinic Foundation, New Orleans, LA 70121, USA.
FAU - Lightell, Daniel Jr
AU  - Lightell D Jr
FAU - Deichmann, Richard E Jr
AU  - Deichmann RE Jr
FAU - Woods, T Cooper
AU  - Woods TC
LA  - eng
GR  - P20 RR018766/RR/NCRR NIH HHS/United States
GR  - P20 RR018766-066844/RR/NCRR NIH HHS/United States
GR  - P20RR018766-06/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Aged
MH  - Animals
MH  - Cell Proliferation/*drug effects
MH  - Diabetes Mellitus/metabolism
MH  - Diabetes Mellitus, Type 2/metabolism
MH  - Drug-Eluting Stents
MH  - Female
MH  - Humans
MH  - Male
MH  - Mammals/metabolism
MH  - Middle Aged
MH  - Muscle, Smooth/metabolism
MH  - Myocytes, Smooth Muscle/*drug effects/metabolism
MH  - Sirolimus/metabolism/*pharmacology
PMC - PMC2891793
MID - NIHMS117983
EDAT- 2009/01/09 09:00
MHDA- 2010/09/21 06:00
PMCR- 2010/06/25
CRDT- 2009/01/09 09:00
PHST- 2009/01/09 09:00 [entrez]
PHST- 2009/01/09 09:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
PHST- 2010/06/25 00:00 [pmc-release]
AID - 10.1097/FJC.0b013e318195b588 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2009 Jan;53(1):86-9. doi: 10.1097/FJC.0b013e318195b588.